Brain Thinning Predicts Alzheimer’s 10 Years Before Symptoms – Neuroscience News

Summary: A study involving 1,500 participants found that cortical gray matter thinning could be an early biomarker for dementia, potentially predicting its development 5 to 10 years before symptoms. This finding suggests that measuring gray matter thickness via MRI could be key in early dementia detection and intervention. Cortical gray matter thinning is a promising biomarker for identifying individuals at high risk of dementia 5 to 10 years before symptoms appear. The study’s findings were consistent across diverse racial and ethnic groups, enhancing the biomarker’s potential applicability. This discovery opens new avenues for early intervention, lifestyle modifications, and the development of targeted therapeutics for dementia.Source: UT San AntonioA strip of brain tissue called cortical gray matter grows thinner in people who go on to develop dementia, and this appears to be an accurate biomarker of the disease five to 10 years before symptoms appear, researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) reported.The researchers, in collaboration with colleagues from The University of California, Davis, and Boston University, conducted an MRI brain imaging study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. They studied 1,000 Massachusetts participants in the Framingham Heart Study and 500 people from a California cohort. The California volunteers included 44% representation of Black and Hispanic participants, whereas the Massachusetts cohort was predominantly non-Hispanic white. Both cohorts were 70 to 74 years of age on average at the time of MRI studies. Repeating the Framingham findings in the more-diverse California cohort “gives us confidence that our results are robust,” said Satizabal, the study’s lead author. Credit: Neuroscience News”The big interest in this paper is that, if we can replicate it in additional samples, cortical gray matter thickness will be a marker we can use to identify people at high risk of dementia,” said study lead author Claudia Satizabal, PhD, of UT Health San Antonio’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. “By detecting the disease early, we are in a better time window for therapeutic interventions and lifestyle modifications, and to do better tracking of brain health to decrease individuals’ progression to dementia.”Repeating the Framingham findings in the more-diverse California cohort “gives us confidence that our results are robust,” Satizabal said.Sifting MRIs for a patternWhile dementias can affect different brain regions, Alzheimer’s disease and frontotemporal dementia impact the cortex, and Alzheimer’s is the most common type of dementia.The study compared participants with and without dementia at the time of MRI. “We went back and examined the brain MRIs done 10 years earlier, and then we mixed them up to see if we could discern a pattern that reliably distinguished those who later developed dementia from those who did not,” said co-author Sudha Seshadri, MD, director of the Glenn Biggs Institute at UT Health San Antonio and senior investigator with the Framingham Heart Study.”This kind of study is only possible when you have longitudinal follow-up over many years as we did at Framingham and as we are building in San Antonio,” Seshadri said. “The people who had the research MRI scans while they were well and kept coming back to be studied are the selfless heroes who make such valuable discoveries, such prediction tools possible.”The results were consistent across populations. Thicker ribbons correlated with better outcomes and thinner ribbons with worse, in general. “Although more studies are needed to validate this biomarker, we’re off to a good start,” Satizabal said. “The relationship between thinning and dementia risk behaved the same way in different races and ethnic groups.”ApplicationsClinical trial researchers could use the thinning biomarker to minimize cost by selecting participants who haven’t yet developed any disease but are on track for it, Seshadri said. They would be at greatest need to try investigational medications, she said.The biomarker would also be useful to develop and evaluate therapeutics, Seshadri noted.Future directionsSatizabal said the team plans to explore risk factors that may be related to the thinning. These include cardiovascular risk factors, diet, genetics and exposure to environmental pollutants, she said.”We looked at APOE4, which is a main genetic factor related to dementia, and it was not related to gray matter thickness at all,” Satizabal said. “We think this is good, because if thickness is not genetically determined, then there are modifiable factors such as diet and exercise that can influence it.”Derived in clinical MRIsCould the MRI gray matter biomarker be used widely someday?”A high proportion of people going to the neurologist get their MRI done, so this thickness value might be something that a neuroradiologist derives,” Seshadri said. “A person’s gray matter thickness might be analyzed as a percentile of the thickness of healthy people for that age.”AcknowledgmentsNational Institutes of Health/National Institute on Aging funding for Alzheimer’s Disease Research Centers (ADRCs) at The University of Texas Health Science Center at San Antonio; The University of California, Davis; and Boston University School of Medicine supported this study.About this Alzheimer’s disease research newsAuthor: Steven Lee
Source: UT San Antonio
Contact: Steven Lee – UT San Antonio
Image: The image is credited to Neuroscience NewsOriginal Research: Open access.
“A novel neuroimaging signature for ADRD risk stratification in the community” by Claudia Satizabal et al. Alzheimer’s & Dementia AbstractA novel neuroimaging signature for ADRD risk stratification in the communityINTRODUCTIONEarly risk stratification for clinical dementia could lead to preventive therapies. We identified and validated a magnetic resonance imaging (MRI) signature for Alzheimer’s disease (AD) and related dementias (ARDR).METHODSAn MRI ADRD signature was derived from cortical thickness maps in Framingham Heart Study (FHS) participants with AD dementia and matched controls. The signature was related to the risk of ADRD and cognitive function in FHS. Results were replicated in the University of California Davis Alzheimer’s Disease Research Center (UCD-ADRC) cohort.RESULTSParticipants in the bottom quartile of the signature had more than three times increased risk for ADRD compared to those in the upper three quartiles (P < 0.001). Greater thickness in the signature was related to better general cognition (P < 0.01) and episodic memory (P = 0.01). Results replicated in UCD-ADRC.DISCUSSIONWe identified a robust neuroimaging biomarker for persons at increased risk of ADRD. Other cohorts will further test the validity of this biomarker.

Author: OpenAI